Aprea Therapeutics (APRE) Competitors

$0.95 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$0.94 -0.01 (-0.53%)

As of 05/22/2026 07:54 PM Eastern

APRE vs. NBRV, ELUT, LITS, TLPH, and INCR

Should you buy Aprea Therapeutics stock or one of its competitors? MarketBeat compares Aprea Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aprea Therapeutics include Nabriva Therapeutics (NBRV), Elutia (ELUT), Lite Strategy (LITS), Talphera (TLPH), and InterCure (INCR). These companies are all part of the "pharmaceutical products" industry.

How does Aprea Therapeutics compare to Nabriva Therapeutics?

Nabriva Therapeutics (NASDAQ:NBRV) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

In the previous week, Aprea Therapeutics' average media sentiment score of 1.00 beat Nabriva Therapeutics' score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Nabriva Therapeutics	Neutral
Aprea Therapeutics	Positive

Aprea Therapeutics has lower revenue, but higher earnings than Nabriva Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A
Aprea Therapeutics	$290K	40.56	-$12.60M	-$1.54	N/A

0.3% of Nabriva Therapeutics shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 1.6% of Nabriva Therapeutics shares are held by company insiders. Comparatively, 13.6% of Aprea Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nabriva Therapeutics has a net margin of -148.11% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -61.03% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%

Nabriva Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

Aprea Therapeutics has a consensus target price of $4.07, suggesting a potential upside of 328.07%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aprea Therapeutics is more favorable than Nabriva Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Aprea Therapeutics beats Nabriva Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Aprea Therapeutics compare to Elutia?

Elutia (NASDAQ:ELUT) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

Elutia has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market.

74.0% of Elutia shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 27.6% of Elutia shares are owned by insiders. Comparatively, 13.6% of Aprea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Elutia has a net margin of 312.09% compared to Aprea Therapeutics' net margin of -4,405.59%. Elutia's return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	312.09%	N/A	-53.97%
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%

Elutia has higher revenue and earnings than Aprea Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.29M	4.04	$53.38M	$0.86	1.35
Aprea Therapeutics	$290K	40.56	-$12.60M	-$1.54	N/A

In the previous week, Elutia had 1 more articles in the media than Aprea Therapeutics. MarketBeat recorded 1 mentions for Elutia and 0 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 1.00 beat Elutia's score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Elutia	Neutral
Aprea Therapeutics	Positive

Elutia currently has a consensus target price of $6.00, indicating a potential upside of 417.24%. Aprea Therapeutics has a consensus target price of $4.07, indicating a potential upside of 328.07%. Given Elutia's stronger consensus rating and higher probable upside, equities research analysts plainly believe Elutia is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Elutia beats Aprea Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Aprea Therapeutics compare to Lite Strategy?

Lite Strategy (NASDAQ:LITS) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Aprea Therapeutics has lower revenue, but higher earnings than Lite Strategy. Lite Strategy is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lite Strategy	$65.30M	0.56	-$15.94M	-$1.60	N/A
Aprea Therapeutics	$290K	40.56	-$12.60M	-$1.54	N/A

Lite Strategy has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -61.03% beat Lite Strategy's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lite Strategy	N/A	-90.81%	-89.33%
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%

Lite Strategy has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

In the previous week, Lite Strategy had 1 more articles in the media than Aprea Therapeutics. MarketBeat recorded 1 mentions for Lite Strategy and 0 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 1.00 beat Lite Strategy's score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Lite Strategy	Neutral
Aprea Therapeutics	Positive

Aprea Therapeutics has a consensus price target of $4.07, indicating a potential upside of 328.07%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aprea Therapeutics is more favorable than Lite Strategy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

52.4% of Lite Strategy shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 1.6% of Lite Strategy shares are owned by company insiders. Comparatively, 13.6% of Aprea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Aprea Therapeutics beats Lite Strategy on 12 of the 16 factors compared between the two stocks.

How does Aprea Therapeutics compare to Talphera?

Talphera (NASDAQ:TLPH) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

37.7% of Talphera shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 3.5% of Talphera shares are owned by insiders. Comparatively, 13.6% of Aprea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Aprea Therapeutics has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30K	1,410.12	-$14.29M	-$0.31	N/A
Aprea Therapeutics	$290K	40.56	-$12.60M	-$1.54	N/A

Talphera has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

Talphera has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -61.03% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-92.98%	-53.22%
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%

In the previous week, Talphera had 3 more articles in the media than Aprea Therapeutics. MarketBeat recorded 3 mentions for Talphera and 0 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 1.00 beat Talphera's score of -0.19 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Talphera	Neutral
Aprea Therapeutics	Positive

Talphera presently has a consensus target price of $3.00, indicating a potential upside of 268.05%. Aprea Therapeutics has a consensus target price of $4.07, indicating a potential upside of 328.07%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aprea Therapeutics is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Aprea Therapeutics beats Talphera on 11 of the 16 factors compared between the two stocks.

How does Aprea Therapeutics compare to InterCure?

InterCure (NASDAQ:INCR) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

InterCure has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. InterCure's return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%

Aprea Therapeutics has a consensus price target of $4.07, suggesting a potential upside of 328.07%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aprea Therapeutics is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Aprea Therapeutics' average media sentiment score of 1.00 beat InterCure's score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
InterCure	Neutral
Aprea Therapeutics	Positive

InterCure has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

8.3% of InterCure shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 0.2% of InterCure shares are held by insiders. Comparatively, 13.6% of Aprea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

InterCure has higher revenue and earnings than Aprea Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.61	-$10.37M	$0.03	29.30
Aprea Therapeutics	$290K	40.56	-$12.60M	-$1.54	N/A

Summary

Aprea Therapeutics beats InterCure on 8 of the 15 factors compared between the two stocks.

Get Aprea Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APRE vs. The Competition

Export

Metric	Aprea Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.76M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-0.62	18.74	21.21	25.65
Price / Sales	40.56	323.98	554.38	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	0.28	7.09	10.37	7.14
Net Income	-$12.60M	$24.45M	$3.57B	$335.98M
7 Day Performance	18.75%	6.38%	6.40%	4.15%
1 Month Performance	2.16%	2.43%	3.53%	2.54%
1 Year Performance	-43.11%	62.98%	34.04%	35.06%

Aprea Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APRE Aprea Therapeutics	4.2513 of 5 stars	$0.95 flat	$4.07 +328.1%	-43.1%	$11.76M	$290K	N/A	7	Positive News Gap Down
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	$45.46M	$35.59M	N/A	70
ELUT Elutia	2.6233 of 5 stars	$1.05 -0.9%	$6.00 +471.4%	-32.6%	$45.35M	$12.29M	1.28	180	Gap Up
LITS Lite Strategy	0.2238 of 5 stars	$1.25 +0.8%	N/A	N/A	$45.09M	$65.30M	N/A	100	Positive News
TLPH Talphera	3.2377 of 5 stars	$0.86 -1.2%	$3.00 +249.9%	+61.1%	$45.02M	$30K	N/A	19

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APRE) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aprea Therapeutics (APRE) Competitors

APRE vs. NBRV, ELUT, LITS, TLPH, and INCR

How does Aprea Therapeutics compare to Nabriva Therapeutics?

Summary

How does Aprea Therapeutics compare to Elutia?

Summary

How does Aprea Therapeutics compare to Lite Strategy?

Summary

How does Aprea Therapeutics compare to Talphera?

Summary

How does Aprea Therapeutics compare to InterCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE vs. The Competition

Aprea Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aprea Therapeutics (APRE) Competitors

APRE vs. NBRV, ELUT, LITS, TLPH, and INCR

How does Aprea Therapeutics compare to Nabriva Therapeutics?

Does the media favor NBRV or APRE?

Which has stronger earnings & valuation, NBRV or APRE?

Do insiders & institutionals hold more shares of NBRV or APRE?

Is NBRV or APRE more profitable?

Which has more risk and volatility, NBRV or APRE?

Do analysts rate NBRV or APRE?

Summary

How does Aprea Therapeutics compare to Elutia?

Which has more risk & volatility, ELUT or APRE?

Do insiders & institutionals believe in ELUT or APRE?

Is ELUT or APRE more profitable?

Which has higher earnings and valuation, ELUT or APRE?

Does the media favor ELUT or APRE?

Do analysts prefer ELUT or APRE?

Summary

How does Aprea Therapeutics compare to Lite Strategy?

Which has stronger valuation & earnings, LITS or APRE?

Is LITS or APRE more profitable?

Which has more risk and volatility, LITS or APRE?

Does the media prefer LITS or APRE?

Do analysts recommend LITS or APRE?

Do insiders & institutionals have more ownership in LITS or APRE?

Summary

How does Aprea Therapeutics compare to Talphera?

Do institutionals & insiders believe in TLPH or APRE?

Which has better earnings & valuation, TLPH or APRE?

Which has more risk & volatility, TLPH or APRE?

Is TLPH or APRE more profitable?

Does the media refer more to TLPH or APRE?

Do analysts prefer TLPH or APRE?

Summary

How does Aprea Therapeutics compare to InterCure?

Is INCR or APRE more profitable?

Do analysts prefer INCR or APRE?

Does the media prefer INCR or APRE?

Which has more volatility & risk, INCR or APRE?

Do institutionals and insiders hold more shares of INCR or APRE?

Which has better earnings & valuation, INCR or APRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE vs. The Competition

Aprea Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools